FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Wyeth - Biotech Market Share Report

Tools

Wyeth market share report featuring Enbrel

Company: Wyeth
2007 Sales:
$2.2 billion
Market share: 3%
CAGR: 38.4%

What they have: Wyeth's top-selling biologic is Enbrel, which it markets with Amgen. The monoclonal antibody is approved for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis and chronic moderate to severe plaque psoriasis.

What to look for: Bapineuzumab--currently in Phase III development--is a humanized monoclonal antibody being investigated for the treatment of Alzheimer's disease and possibly glaucoma.

Bookmark and Share
Get Your FREE FierceBiotech Email Newsletter:
Comments (1) | Post a comment

Comments

Looks like the USA is about to loose its biotech industry to china after we have made a fortune for the drugmakers.SHAME on THEM>

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.